In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...